Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > New Discoveries Confirm and Enhance CombiMatrix's Microarray Test for Autism

Abstract:
CombiMatrix Corporation (Nasdaq:CBMX) announced that today's publication in the American Journal of Human Genetics by Dr. Steve Scherer and colleagues further implicate genomic copy number variation (CNV) in the etiology of Autism Spectrum Disorder (ASD) elevating the importance of the CBMX ATScan(tm) 1.0 microarray test. The study reports the discovery of a chromosome 16p11.2 region in one percent of ASD patients identical to that described last week in the New England Journal of Medicine (Daly et al., NEJM), as well as numerous additional previously unreported ASD-risk genes. CBMX is proud to announce that, as a function of its unparalleled ability to rapidly enhance and clinically validate its genomic arrays, these new loci exist or are being added to the ATScan(tm) 1.0 establishing the CBMX platform as the most up-to-date and comprehensive diagnostic test of its kind for ASD. Moreover, as a function of CBMX's commitment to responsible and affordable diagnostics testing, the enhanced ATScan(tm) remains priced as the most affordable comparable test in the industry. We encourage physicians and patients to contact us at 949-753-0624 for more information.

New Discoveries Confirm and Enhance CombiMatrix's Microarray Test for Autism

MUKILTEO, WA | Posted on January 17th, 2008

In the American Journal of Human Genetics publication, researchers at the Hospital for Sick Children (SickKids) in Toronto discovered several new genomic variations, increasing the number of identified CNV regions associated to ASD. Dr. Steve Scherer, senior scientist in Genetics & Genomic Biology at SickKids and professor of Molecular Genetics at the University of Toronto noted that, "Our finding of CNVs in seven percent of autistic children not seen in their parents or controls has important clinical implications. Our data indicates that the application of microarrays can have great utility in clinical assessment of undetected syndromes underlying ASD, making it crucial to rapidly translate our basic research discoveries into validated clinical tests available to families," he said.

Dr. Mansoor Mohammed, President and CEO of CombiMatrix Molecular Diagnostics noted that, "We have dedicated considerable effort in mining the literature and leveraging our partnerships to move significant evidence-based research into quality-assured clinical diagnostics. These recent discoveries validate our business plan to establish ourselves as the preeminent provider of genome-based diagnostics. Not only am I proud to see the fruition of our efforts in the rapid development and deployment of our ATScan(tm) test, but also of the exciting pipeline of products we are currently developing and our commitment to their clinical relevance and affordability."

The following are links to the American Journal of Human Genetics article referenced above, as well as the press release from the Hospital for Sick Children (SickKids):
http://www.ajhg.org/AJHG/latestarticles ; http://www.sickkids.ca/mediaroom/custom/structuralchanges08.asp .

####

About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology company that develops and sells proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security, as well as other potential markets where our products and services could be utilized. The technologies we have developed include methods to produce DNA arrays for use in identifying and determining the roles of genes, gene mutations and proteins. These technologies have a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or call toll free: 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form S-1, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please click here

Contacts:
CombiMatrix Corporation
Investor Relations
Amit Kumar
(425) 493-2000
Fax (425) 493-2010

Copyright © PrimeNewswire, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

National Science Foundation Selects SUNY Poly CNSE for Expanded $2.1M Northeast Advanced Technological Education Center: NSF Center Locates to NanoCollege in Support of Flourishing Tech Industry in NYS September 1st, 2015

RUSNANOPRIZE Directorate Announces New Deadline for Nominations Submission September 11, 2015 September 1st, 2015

Nanomedicine

Using DNA origami to build nanodevices of the future September 1st, 2015

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Iranian Scientists Use Artemisia Annua Plant to Produce Breast Cancer Drugs August 29th, 2015

Discoveries

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

Hot electrons point the way to perfect light absorption: Physicists study how to achieve perfect absorption of light with the help of rough ultrathin films September 1st, 2015

Using DNA origami to build nanodevices of the future September 1st, 2015

Announcements

Phagraphene, a 'relative' of graphene, discovered September 2nd, 2015

A marine creature's magic trick explained: Crystal structures on the sea sapphire's back appear differently depending on the angle of reflection September 2nd, 2015

Waste coffee used as fuel storage: Scientists have developed a simple process to treat waste coffee grounds to allow them to store methane September 2nd, 2015

Nanotech could rid cattle of ticks, with less collateral damage September 1st, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic